CDC25A

CDC25A CDC25A is a human protein phosphatase that activates cyclin-dependent kinases to drive cell cycle transitions. First characterized in yeast genetic screens and later cloned from human cDNA libraries, CDC25A functions at key control points to coordinate proliferation, DNA repair, and checkpoint signaling. It has been studied extensively in the contexts of oncogenesis, checkpoint control, and targeted cancer therapy.

Function and Mechanism

CDC25A encodes a dual-specificity phosphatase that removes inhibitory phosphates from cyclin-dependent kinases such as CDK1 and CDK2 to promote progression through S phase and entry into mitosis. Biochemical assays and structural studies reveal a catalytic domain that dephosphorylates phosphothreonine and phosphotyrosine residues, enabling activation of complexes such as Cyclin A–CDK2 and Cyclin B–CDK1. Genetic disruption experiments in model organisms including Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Mus musculus highlight conserved roles in cell cycle timing and checkpoint override. CDC25A action is tightly coupled to regulatory circuits involving checkpoint kinases and ubiquitin ligases such as SCF complex members, integrating signals from upstream factors like ATM kinase, ATR kinase, and CHK1.

Regulation and Post-translational Modifications

CDC25A is regulated by phosphorylation, ubiquitination, and controlled proteolysis. Checkpoint kinases including CHEK1 and CHEK2 phosphorylate CDC25A at multiple sites, creating phosphodegrons recognized by F-box proteins such as β-TrCP within the SCF complex, targeting it for ubiquitin-mediated degradation by the 26S proteasome. Growth factor signaling via receptor tyrosine kinases like EGFR and downstream kinases such as AKT1 and ERK1/2 can phosphorylate or otherwise modify CDC25A to alter stability and subcellular localization. Additional post-translational modifiers include SUMOylation enzymes linked to PIAS1 and acetyltransferases associated with p300, which have been implicated in modulating CDC25A activity in response to developmental and stress cues. Proteomic screens and mass spectrometry studies in cell lines derived from HeLa and HEK293 cells document phosphorylation dynamics across the cell cycle and after exposure to agents such as ionizing radiation and ultraviolet light.

Role in Cell Cycle and DNA Damage Response

CDC25A functions at the G1/S and G2/M transitions, facilitating replication origin firing and mitotic entry by activating CDK complexes. At G1/S, CDC25A promotes E2F-dependent transcriptional programs indirectly through CDK2 activation, coordinating with tumor suppressors including RB1 and transcription factors exemplified by E2F1. In response to DNA damage, sensors like ATM and ATR initiate cascades that activate checkpoint kinases; these kinases phosphorylate CDC25A to inhibit its activity and induce degradation, enforcing cell cycle arrest to permit DNA repair pathways such as homologous recombination involving BRCA1 and RAD51. Failure to regulate CDC25A appropriately can lead to replication stress, genomic instability, and propagation of DNA lesions that are central to models of tumor initiation described in studies of TP53-deficient backgrounds.

Clinical Significance and Disease Associations

Aberrant expression or stabilization of CDC25A is observed in multiple human malignancies including breast cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, and acute myeloid leukemia. Overexpression correlates with poor prognosis and resistance to DNA-damaging chemotherapeutics in clinical cohorts analyzed by consortia such as The Cancer Genome Atlas and translational groups at institutions like MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. CDC25A has been pursued as a pharmacologic target; small-molecule inhibitors and allosteric modulators have been developed and evaluated in preclinical studies at pharmaceutical companies including Pfizer and Novartis, as well as in academic drug-discovery programs at Harvard Medical School and University of California, San Francisco. Beyond oncology, dysregulation of CDC25A has been implicated in developmental syndromes and proliferative disorders studied in clinical genetics units such as Mayo Clinic and Johns Hopkins Hospital.

Interactions and Protein Partners

CDC25A interacts with a network of kinases, ubiquitin ligases, scaffold proteins, and cell cycle regulators. Direct and functional partners include CDKs CDK1 and CDK2, cyclins Cyclin A2 and Cyclin B1, checkpoint kinases CHEK1 and CHEK2, ubiquitin-recognition F-box proteins such as β-TrCP1 (BTRC), and components of the SCF complex including SKP1 and CUL1. Interactions with tumor suppressors and transcriptional regulators such as TP53, BRCA1, and E2F1 integrate CDC25A into DNA damage and proliferation circuits. Additional binding partners identified by affinity purification–mass spectrometry include chaperones like HSP90AA1, nuclear transport factors such as CRM1 (XPO1), and SUMO pathway factors including SENP1. Mapping of these interactions in databases curated by groups at European Bioinformatics Institute, National Center for Biotechnology Information, and consortium projects has facilitated mechanistic models of how CDC25A coordinates checkpoint recovery, replication origin firing, and oncogenic signaling.

Category:Human proteins